TMT1A and thyroid cancer: EZH2 interacts with the CpG sites of the METTL7A gene body in thyroid cancer, recruiting MBD2 and rejecting RNA pol II, resulting in METTL7A silencing, which in turn mediates abnormal tumour metabolism [108].